SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-047742
Filing Date
2024-11-26
Accepted
2024-11-26 08:05:36
Documents
14
Period of Report
2024-11-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 65651
2 ex10-1.htm EX-10.1 15655
  Complete submission text file 0001493152-24-047742.txt   264809

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnfa-20241125.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tnfa-20241125_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tnfa-20241125_pre.xml EX-101.PRE 24167
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3838
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241498206
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)